The economic burden of pulmonary arterial hypertension in Spain

作者：Néboa Zozaya, Fernando Abdalla, Ignacio Moreno, Carlos Crespo-Diz, Ana M. Ramírez Gallardo, Joaquín Rueda Soriano, Macarena Alcalá Galán, Álvaro Hidalgo‐Vega · 发表于：BMC Pulmonary Medicine · 年份：2022 · DOI：10.1186/s12890-022-01906-2 · 被引用次数：21 · 研究领域：Pulmonary Hypertension Research and Treatments、Chronic Obstructive Pulmonary Disease (COPD) Research、Blood Pressure and Hypertension Studies

BACKGROUND: Pulmonary Arterial Hypertension (PAH) is a rare, debilitating, and potentially fatal disease. This study aims to quantify the economic burden of PAH in Spain. METHODS: The study was conducted from a societal perspective, including direct and indirect costs associated with incident and prevalent patients. Average annual costs per patient were estimated by multiplying the number of resources consumed by their unit cost, differentiating the functional class (FC) of the patient. Total annual costs per FC were also calculated, taking the 2020 prevalence and incidence ranges into account. An expert committee validated the information on resource consumption and provided primary information on pharmacological consumption. Unit costs were estimated using official tariffs and salaries in Spain. A deterministic sensitivity analysis was conducted to test the uncertainty of the model. RESULTS: The average annual total cost was estimated at €98,839 per prevalent patient (FC I-II: €65,233; FC III: €103,736; FC IV: €208,821), being €42,110 for incident patients (FC I-II: €25,666; FC III: €44,667; FC IV: €95,188). The total annual cost of PAH in Spain, taking into account a prevalence between 16.0 and 25.9 cases per million adult inhabitants (FC I-II 31.8%; FC III 61.3%; FC IV 6.9%) and an incidence of 3.7, was estimated at €67,891,405 to €106,131,626, depending on the prevalence considered. Direct healthcare costs accounted for 64% of the total cost, followed by indirect costs (...